Skip to content
PreclinicalResearch compoundModerate evidence

Phenylpiracetam

Phenyl group on the piracetam scaffold. Stimulant racetam + dopaminergic modulator, WADA-banned in competition.

NootropicPerformance BoosterRacetamStimulantFocusAcetylcholineDopamineNorepinephrineAnti-fatigue

Pharmacology

ClassRacetam · Stimulant · Focus
Primary targetα4β2 nicotinic ACh receptor agonist
Targets4 receptor targets
Half-life3-5 h
Onset30-60 min
EvidenceModerate evidence
Affected systemsAcetylcholineDopamineNorepinephrineAnti-fatigue

Contents

WHAT IS PHENYLPIRACETAM?

Detailed overview

Phenylpiracetam (Phenotropil, Carphedon) is a phenyl-modified piracetam analogue, developed in Russia originally to support cognitive and physical performance under stress (cosmonaut program). A stimulant-class nootropic with dopaminergic + noradrenergic modulation and AMPA positive allosteric modulation. WADA-banned (S6 stimulants) in competition. Rx in Russia; research chemical in EU/USA.

Mechanism

Stimulant racetam + DAT modulator

Half-life

3-5 hours

Onset

30-60 min

Legal status

Russia Rx, WADA banned

Receptor profile

  • α4β2 nicotinic ACh receptorStrong
  • Dopamine transporter (DAT)Moderate
  • Piracetam-type AMPA / membrane / ion-channelWeak
  • Physical stamina / cold toleranceModerate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Insomnia and disrupted sleep, especially with afternoon dosing (stimulant nature)
  • Headache, often from choline depletion (racetam component, eased by a choline source)
  • Irritability and anxiety, jitteriness (dopaminergic/noradrenergic stimulation)
  • Rapid heartbeat and palpitations, mild blood pressure rise
  • Rapid tolerance with daily use, diminishing effect
  • Appetite suppression and mild gastrointestinal discomfort

Contraindications · 6

  • Pregnancy and breastfeeding, avoid due to insufficient safety data
  • Strictly avoid with MAO inhibitors (risk of hypertensive crisis)
  • Additive tachycardia and blood pressure rise with other stimulants (caffeine, amphetamines)
  • Avoid with unstable cardiac disease, arrhythmia, severe hypertension
  • Active anxiety disorder and insomnia, the stimulant nature may worsen them
  • Prohibited for competitive athletes (WADA S6 stimulant category)

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Phenylpiracetam was originally developed in Russia to support cosmonauts' mental and physical performance under demanding conditions. It's used for a quick, stimulant-like boost in alertness and attention, and Russian military and clinical data also point to improved physical stamina, cold tolerance and stress resilience; it's banned by WADA in competitive sports.

Telegram

Have a question about Phenylpiracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H14N2O2
UpdatedJune 19, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.